Columbus: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) is one of four cancer centers involved in testing a new “nanomedicine” agent – known as BXQ-350 while in testing – in advanced solid tumors, including difficult-to-treat malignant brain tumors. BXQ-350 combines a protein called Saposin C, which is naturally expressed in humans, with nanobubbles of a fat molecule called DOPS. This combination creates a treatment agent that has the ability to selectively target cancerous tumor cells and then kill them, largely sparing the surrounding healthy tissues. These fat nanoparticles can also penetrate the blood brain barrier, which researchers say makes them particularly useful against malignant brain tumors.
“BXQ-350 is the first agent in this class of drugs and has unique
properties not seen in conventional cancer treatments. It is made of
natural substances present in humans. Lab experiments have shown the
agent has the ability to target cancer cells specifically and eliminate
them,” says Vinay Puduvalli,
MD, director of neuro-oncology at the OSUCCC – James. “I believe that
this research can potentially open new doors to the treatment of
malignant brain tumors and other advanced cancers”
Recently reported clinical results from
the phase I dose-escalation study show that the agent is well tolerated
by patients; no dose-limiting toxicities have been observed, and no
serious adverse events have been attributed to the therapy. The trial is
accruing additional patients through an expanded phase IB trial, which is expected to enroll about 40 patients nationwide.
Patients with malignant brain tumors and advanced solid cancerous
tumors who have not responded to other therapies may qualify for this
therapy. BXQ-350 is available as part of a clinical trial
underway only at the OSUCCC – James, University of New Mexico Cancer
Center, University of Cincinnati Barrett Center and University of
Kentucky Markey Cancer Center.
The trial is sponsored by Bexion Pharmaceuticals. Puduvalli has no
financial interests in Bexion Pharmaceuticals, manufacturer of BXQ-350.
To learn more about clinical trials at the OSUCCC – James, visit cancer.osu.edu/clinicaltrials or call 1-800-293-5066.